Cell Reports (Feb 2022)
Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses
- Harikrishnan Balachandran,
- Chansavath Phetsouphanh,
- David Agapiou,
- Anurag Adhikari,
- Chaturaka Rodrigo,
- Mohamed Hammoud,
- Lok Bahadur Shrestha,
- Elizabeth Keoshkerian,
- Money Gupta,
- Stuart Turville,
- Daniel Christ,
- Cecile King,
- Sarah C. Sasson,
- Adam Bartlett,
- Branka Grubor-Bauk,
- William Rawlinson,
- Anupriya Aggarwal,
- Alberto Ospina Stella,
- Vera Klemm,
- Michael M. Mina,
- Jeffrey J. Post,
- Bernard Hudson,
- Nicky Gilroy,
- Pam Konecny,
- Golo Ahlenstiel,
- Dominic E. Dwyer,
- Tania C. Sorrell,
- Anthony Kelleher,
- Nicodemus Tedla,
- Andrew R. Lloyd,
- Marianne Martinello,
- Rowena A. Bull
Affiliations
- Harikrishnan Balachandran
- School of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia; The Kirby Institute, UNSW, Sydney, NSW, Australia
- Chansavath Phetsouphanh
- The Kirby Institute, UNSW, Sydney, NSW, Australia
- David Agapiou
- The Kirby Institute, UNSW, Sydney, NSW, Australia
- Anurag Adhikari
- School of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia; The Kirby Institute, UNSW, Sydney, NSW, Australia; Department of Infection and Immunology, Kathmandu Research Institute for Biological Sciences, Lalitpur, Nepal
- Chaturaka Rodrigo
- School of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia; The Kirby Institute, UNSW, Sydney, NSW, Australia
- Mohamed Hammoud
- The Kirby Institute, UNSW, Sydney, NSW, Australia
- Lok Bahadur Shrestha
- School of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia; The Kirby Institute, UNSW, Sydney, NSW, Australia
- Elizabeth Keoshkerian
- The Kirby Institute, UNSW, Sydney, NSW, Australia
- Money Gupta
- School of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia; The Kirby Institute, UNSW, Sydney, NSW, Australia
- Stuart Turville
- The Kirby Institute, UNSW, Sydney, NSW, Australia
- Daniel Christ
- Garvan Institute of Medical Research, Sydney, NSW, Australia
- Cecile King
- Garvan Institute of Medical Research, Sydney, NSW, Australia
- Sarah C. Sasson
- The Kirby Institute, UNSW, Sydney, NSW, Australia
- Adam Bartlett
- The Kirby Institute, UNSW, Sydney, NSW, Australia; Sydney Children's Hospital Randwick, Randwick, NSW, Australia
- Branka Grubor-Bauk
- Viral Immunology Group, The University of Adelaide & Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia
- William Rawlinson
- School of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia; Serology and Virology Division, Department of Microbiology, New South Wales Health Pathology, Randwick, Sydney, NSW, Australia
- Anupriya Aggarwal
- The Kirby Institute, UNSW, Sydney, NSW, Australia
- Alberto Ospina Stella
- The Kirby Institute, UNSW, Sydney, NSW, Australia
- Vera Klemm
- The Kirby Institute, UNSW, Sydney, NSW, Australia
- Michael M. Mina
- Northern Beaches Hospital, Frenchs Forest, NSW, Australia
- Jeffrey J. Post
- Prince of Wales Hospital, Sydney, NSW, Australia; Prince of Wales Clinical School, UNSW, Sydney, NSW, Australia
- Bernard Hudson
- Royal North Shore Hospital, Sydney, NSW, Australia
- Nicky Gilroy
- Westmead Hospital, Sydney, NSW, Australia
- Pam Konecny
- St George Hospital, Sydney, NSW, Australia
- Golo Ahlenstiel
- Blacktown Mt Druitt Hospital, Blacktown, NSW, Australia; Blacktown Clinical School, School of Medicine, Western Sydney University, Mount Druitt, NSW, Australia
- Dominic E. Dwyer
- New South Wales Health Pathology – Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW, Australia
- Tania C. Sorrell
- University of Sydney Institute for Infectious Diseases and Faculty of Medicine and Health, Westmead, NSW, Australia
- Anthony Kelleher
- The Kirby Institute, UNSW, Sydney, NSW, Australia
- Nicodemus Tedla
- School of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia
- Andrew R. Lloyd
- The Kirby Institute, UNSW, Sydney, NSW, Australia
- Marianne Martinello
- The Kirby Institute, UNSW, Sydney, NSW, Australia; Prince of Wales Hospital, Sydney, NSW, Australia
- Rowena A. Bull
- School of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia; The Kirby Institute, UNSW, Sydney, NSW, Australia; Corresponding author
- Journal volume & issue
-
Vol. 38,
no. 6
p. 110345
Abstract
Summary: Understanding the long-term maintenance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity is critical for predicting protection against reinfection. In an age- and gender-matched cohort of 24 participants, the association of disease severity and early immune responses on the maintenance of humoral immunity 12 months post-infection is examined. All severely affected participants maintain a stable subset of SARS-CoV-2 receptor-binding domain (RBD)-specific memory B cells (MBCs) and good neutralizing antibody breadth against the majority of the variants of concern, including the Delta variant. Modeling these immune responses against vaccine efficacy data indicate a 45%–76% protection against symptomatic infection (variant dependent). Overall, these findings indicate durable humoral responses in most participants after infection, reasonable protection against reinfection, and implicate baseline antigen-specific CD4+ T cell responses as a predictor of maintenance of antibody neutralization breadth and RBD-specific MBC levels at 12 months post-infection.
